Compare BCAL & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BCAL | BWAY |
|---|---|---|
| Founded | 2001 | 2003 |
| Country | United States | Israel |
| Employees | N/A | 129 |
| Industry | Major Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 672.6M | 578.5M |
| IPO Year | 2020 | N/A |
| Metric | BCAL | BWAY |
|---|---|---|
| Price | $20.98 | $16.41 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $20.67 | $13.25 |
| AVG Volume (30 Days) | ★ 244.8K | 76.6K |
| Earning Date | 04-28-2026 | 05-13-2026 |
| Dividend Yield | ★ 2.15% | N/A |
| EPS Growth | ★ 777.27 | N/A |
| EPS | ★ 0.42 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $309.69 |
| Revenue Next Year | $6.67 | $26.21 |
| P/E Ratio | ★ $50.52 | $81.98 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.57 | $11.35 |
| 52 Week High | $21.71 | $26.63 |
| Indicator | BCAL | BWAY |
|---|---|---|
| Relative Strength Index (RSI) | 55.65 | 61.41 |
| Support Level | $17.97 | $15.97 |
| Resistance Level | $21.50 | $17.82 |
| Average True Range (ATR) | 0.55 | 0.71 |
| MACD | -0.03 | 0.18 |
| Stochastic Oscillator | 48.84 | 81.51 |
California BanCorp is a relationship-focused community bank offering commercial loan and deposit products, along with other services delivered directly or through strategic alliances, to business and individual customers in its target markets. The Company provides financial products and services to individuals, professionals, and small to medium-sized businesses through its branch and commercial banking offices serving California. Its lending products consist mainly of construction and land development loans, real estate loans, C&I loans, and consumer loans, and it is a Preferred SBA Lender, while its deposit products consist mainly of demand deposit, money market, and certificates of deposit. The Company operates in one reportable segment, commercial banking.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.